title: Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy.
abstract: METHODS
  Intralesional recombinant interferon alfa-2b has been shown to be effective in the treatment of actinic keratoses and basal cell carcinomas. This open-label study was designed to evaluate the effectiveness and cosmetic result of this therapy on actinically induced, primary cutaneous squamous cell carcinomas. Thirty-six squamous cell carcinomas (28 invasive lesions and 8 in situ lesions) ranging in size from 0.5 to 2.0 cm in the longest dimension were treated with interferon alfa-2b 1.5 million units injected intralesionally three times per week for 3 weeks. Eighteen weeks following therapy, the treatment sites were excised and examined for histologic evidence of remaining tumor.
  
  
  RESULTS
  Thirty-three (97.1%) of 34 evaluable lesions revealed an absence of squamous cell carcinoma histologically after therapy, although three biopsy specimens (8.8%) obtained after treatment showed actinic keratoses, for an overall complete response rate of 88.2%. The lesion not eliminated after treatment was an invasive squamous cell carcinoma. The investigators and patients independently judged 93.9% of cases to have a very good or excellent cosmetic result. Adverse reactions were limited to those influenzalike symptoms well recognized to occur with interferon therapy and these were well tolerated. Only one patient discontinued therapy due to side effects.
  
  
  CONCLUSIONS
  This trial demonstrates that intralesional interferon is effective in the treatment of small sun-induced squamous cell carcinomas with well-tolerated side effects and a highly acceptable cosmetic result.
authors.affiliation: University of Arizona College of Medicine.
authors.forename: L
authors.initials: L
authors.lastname: Edwards
authors.forename: B
authors.initials: B
authors.lastname: Berman
authors.forename: R P
authors.initials: RP
authors.lastname: Rapini
authors.forename: D A
authors.initials: DA
authors.lastname: Whiting
authors.forename: S
authors.initials: S
authors.lastname: Tyring
authors.forename: H T
authors.initials: HT
authors.lastname: Greenway
authors.forename: S P
authors.initials: SP
authors.lastname: Eyre
authors.forename: D J
authors.initials: DJ
authors.lastname: Tanner
authors.forename: E L
authors.initials: EL
authors.lastname: Taylor
authors.forename: E
authors.initials: E
authors.lastname: Peets
mesh_terms: D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000473:pathology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D004954:Esthetics; D005260:Female; D005350:Fibroma / Q000473:pathology / Q000628:therapy; D006801:Humans; D015552:Injections, Intralesional; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007642:Keratosis / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011994:Recombinant Proteins; D012074:Remission Induction; D012878:Skin Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins